Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug

Published: 2017-12-14 15:06:54

Updated: 2017-12-14 15:06:54

Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December.

The paper, generally managed by Circulatory Internal Medicine Professor Hyo-Soo Kim at Seoul National University Hospital proved Rosumega’s safety and efficacy through the Phase ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.